Amgen Inc. (NASDAQ:AMGN) Shares Purchased by James Investment Research Inc.

James Investment Research Inc. boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 2.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,109 shares of the medical research company’s stock after buying an additional 116 shares during the quarter. James Investment Research Inc.’s holdings in Amgen were worth $1,324,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of AMGN. Vanguard Group Inc. boosted its holdings in Amgen by 6.2% in the first quarter. Vanguard Group Inc. now owns 52,088,210 shares of the medical research company’s stock valued at $14,809,720,000 after purchasing an additional 3,045,657 shares during the last quarter. Capital International Investors grew its holdings in Amgen by 547.8% during the first quarter. Capital International Investors now owns 7,005,269 shares of the medical research company’s stock worth $1,991,738,000 after acquiring an additional 5,923,915 shares during the period. Pathway Financial Advisers LLC grew its holdings in Amgen by 33,125.4% during the third quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company’s stock worth $1,437,115,000 after acquiring an additional 4,446,757 shares during the period. Dimensional Fund Advisors LP raised its position in Amgen by 6.4% during the second quarter. Dimensional Fund Advisors LP now owns 2,701,631 shares of the medical research company’s stock valued at $844,137,000 after acquiring an additional 162,223 shares in the last quarter. Finally, International Assets Investment Management LLC lifted its holdings in Amgen by 6,812.4% in the third quarter. International Assets Investment Management LLC now owns 2,523,387 shares of the medical research company’s stock valued at $8,130,610,000 after acquiring an additional 2,486,882 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AMGN. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a report on Monday, September 16th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 price objective (up previously from $375.00) on shares of Amgen in a report on Wednesday, August 7th. Robert W. Baird reiterated an “underperform” rating and issued a $215.00 price objective on shares of Amgen in a research report on Wednesday, September 25th. UBS Group dropped their target price on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday. Finally, Morgan Stanley reduced their price target on Amgen from $310.00 to $303.00 and set an “equal weight” rating for the company in a report on Thursday, July 11th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $333.50.

Amgen Stock Performance

NASDAQ:AMGN opened at $319.22 on Friday. The company has a market cap of $171.53 billion, a P/E ratio of 40.87, a P/E/G ratio of 2.84 and a beta of 0.61. Amgen Inc. has a twelve month low of $260.52 and a twelve month high of $346.85. The company’s 50-day moving average price is $324.47 and its 200-day moving average price is $315.19. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 181.58%. The business’s revenue was up 23.2% on a year-over-year basis. During the same period last year, the company posted $4.96 EPS. On average, sell-side analysts forecast that Amgen Inc. will post 19.48 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.82%. The ex-dividend date is Monday, November 18th. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.